PDIA3 and esophageal squamous cell carcinoma: Taken together, these data suggest that MYC, PDIA3, and ITGA5B1 may serve as potential therapeutic targets for ESCC treatment, and cotargeting of these biomarkers might be more effective than targeting a single biomarker alone.